EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05)

Antonio J Conde-Moreno, Fernando López-Campos, Asunción Hervás, Virginia Morillo, Agustina Méndez, María D M Puertas, Jeannette Valero-Albarrán, Alfonso Gómez Iturriaga, Mikel Rico, María L Vázquez, Pilar M Samper Ots, Luis A Perez-Romasanta und 7 weitere

Practical Radiation Oncology · 2024

DOI: 10.1016/j.prro.2024.04.022 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Practical Radiation Oncology, 2024. Verfasst von Antonio J Conde-Moreno und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department Radiation Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain. Electronic address: conde_ant@gva.es. Hauptthemen laut MEDLINE: Radiosurgery, Androgen Antagonists, Prostatic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: SBRT-Spanish Group-05 (ClinicalTrials.gov.Identifier: NCT02192788) is a collaborative (SBRT-SG, Grupo de Investigación Clínica en Oncología Radioterápica, and Sociedad Española de Oncología Radioterápica) prospective multicenter phase II trial testing stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT) in patients with oligorecurrent prostate cancer. METHODS AND MATERIALS: Two cohorts of patients with prostate cancer in an oligorecurrent stage (hormone-sensitive in the principal cohort and castration-resistant in the exploratory cohort) were assigned to receive ADT and SBRT for at least 24 months from the time of the enrollment. Concomitant treatment with chemotherapy, abiraterone, or enzalutamide was not allowed. Oncologic outcomes were assessed in both cohorts. Toxicity was prospectively analyzed. RESULTS: From 2014 to 2019, 81 patients with a total of 126 lesions from 14 centers met the inclusion criteria, 14 of whom were castration-resistant. With a median follow-up of 40 months (12-58 months), 3-year local recurrence-free survival was 92.5% (95% CI, 79.9%-96.3%) and 85.7% (95% CI, 48.2%-95.6%) in the principal and exploratory cohorts, respectively. In the principal cohort, biochemical relapse-free survival and metastasis progression-free survival at 1, 2, and 3 years were 91% (95% CI, 81%-95.8%), 73.7% (95% CI, 61.1%-82.8%), 50.6% (95% CI, 36.2%-63.3%), and 92% (95% CI, 83%-97%), 81% (95% CI, 70%-89%), and 67% (95% CI, 53%-77%), respectively. In the exploratory cohort, metastasis progression-free survival at 1, 2, and 3 years was 64% (95% CI, 34%-83%), 43% (95% CI, 18%-66%), and 26% (95% CI, 7%-51%), respectively. None of the patients developed grade III or higher toxicity or symptoms related to local progression, and only 2 (2.4%) patients developed grade II toxicity. CONCLUSIONS: The combination of SBRT and ADT is safe and shows favorable clinical outcomes in patients with hormone-sensitive and castration-resistant prostate cancer. Validation studies are needed in patients with castration-resistant prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryAndrogen AntagonistsProstatic NeoplasmsHumansMaleAgedMiddle AgedAged, 80 and overProspective StudiesNeoplasm MetastasisProstatic Neoplasms, Castration-Resistant

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Department Radiation Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain. Electronic address: conde_ant@gva.es.
  • Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Department of Radiation Oncology, Hospital Provincial de Castellón, Spain.
  • Department of Radiation Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Department Radiation Oncology, Hospital Miguel Servet, Zaragoza, Spain.
  • Department of Radiation Oncology, Hospital HM, Madrid, Spain.

Zitieren

APA

Conde-Moreno, A. J., López-Campos, F., Hervás, A., Morillo, V., Méndez, A., Puertas, M. D. M., Valero-Albarrán, J., Gómez Iturriaga, A., Rico, M., Vázquez, M. L., Samper Ots, P. M., Perez-Romasanta, L. A., Pastor, J., Ibáñez, C., Ferrer, F., Zapatero, A., García-Blanco, A. S., Rodríguez, A., & Ferrer, C. (2024). A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05). Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2024.04.022

Vancouver

Conde-Moreno AJ, López-Campos F, Hervás A, Morillo V, Méndez A, Puertas MDM, et al. A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05). Practical Radiation Oncology. 2024. doi:10.1016/j.prro.2024.04.022

BibTeX
@article{CondeMoreno2024,
  author = {Conde-Moreno, Antonio J and López-Campos, Fernando and Hervás, Asunción and Morillo, Virginia and Méndez, Agustina and Puertas, María D M and Valero-Albarrán, Jeannette and Gómez Iturriaga, Alfonso and Rico, Mikel and Vázquez, María L and Samper Ots, Pilar M and Perez-Romasanta, Luis A and Pastor, Jorge and Ibáñez, Carmen and Ferrer, Ferrán and Zapatero, Almudena and García-Blanco, Ana S and Rodríguez, Aurora and Ferrer, Carlos},
  title = {A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05)},
  journal = {Practical Radiation Oncology},
  year = {2024},
  doi = {10.1016/j.prro.2024.04.022}
}
Kostenlos starten →